Bone stroma inhibition in prostate cancer

Michael A. Carducci, Daniel Keizman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Improved understanding of prostate cancer biology in recent years has led to the development of new targeted agents for the treatment of castration-resistant prostate cancer, many of which are particularly effective on osseous disease, which is predominant in prostate cancer. We reviewed here some of these promising agents. Data from early Phase I/II trials are promising. In Phase III studies, the RANK ligand inhibitor denosumab was associated with a delay in the occurrence of bone metastasis, and a reduction in the incidence of skeletal-related events. With endothelin receptor antagonists, Phase III results have been disappointing. The results of a Phase III trial with the a-radiation emitter alpharadin are expected soon. The SRC tyrosine kinase inhibitors are also being tested in randomized trials.

Original languageEnglish (US)
Title of host publicationAdvances in Bone Metastasis Management
PublisherFuture Medicine Ltd.
Pages31-42
Number of pages12
ISBN (Electronic)9781780840307
ISBN (Print)9781780841151
DOIs
StatePublished - Mar 1 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Bone stroma inhibition in prostate cancer'. Together they form a unique fingerprint.

Cite this